NCT07438626
- Conditions
- Phase II, SMARCB1-deficient Renal Medullary Carcinoma, Sacituzumab, +1 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
SMARCB1-deficient Renal Medullary Carcinoma
Explore clinical trials studying SMARCB1-deficient Renal Medullary Carcinoma. Study availability and eligibility vary by location and protocol.
1 public trial
1 recruiting study